{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T06:49:34Z","timestamp":1776840574706,"version":"3.51.2"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Most patients with hepatocellular carcinoma (HCC) are diagnosed at intermediate or advanced stages, when curative resection is not feasible. Conversion therapy aiming to downstage tumors and enable surgical resection has emerged as a potential strategy. We performed an exploratory, single-arm pilot study to assess the efficacy and safety of transarterial chemoembolization (TACE) combined with lenvatinib and the envafolimab in this setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center, open-label, single-arm pilot trial enrolled patients with Barcelona Clinic Liver Cancer stage B or C unresectable HCC between April and September 2024. Patients received conventional TACE combined with oral lenvatinib and subcutaneous envafolimab until surgical conversion, disease progression, unacceptable toxicity, or death. The primary endpoint was the conversion rate to curative-intent resection. Secondary endpoints included objective response rate (ORR), disease control rate (DCR), pathological response, progression-free survival (PFS), overall survival (OS), and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifteen patients were enrolled. According to mRECIST criteria, the ORR was 53.3% and the DCR was 86.7%. Nine patients (60.0%) achieved sufficient tumor downstaging to undergo curative-intent surgery, and all achieved R0 resection. Pathological complete or major response was observed in five resected patients (55.6%). After a median follow-up of 16 months, the estimated median PFS was 12.0 months. One patient died during follow-up, yielding a 1-year OS of 100% and an 18-month OS of 93.3%. Treatment-emergent adverse events were consistent with the known profiles of TACE, lenvatinib, and envafolimab; however, gastrointestinal bleeding was observed and represents an important safety concern that warrants careful risk stratification and proactive management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this small pilot study, TACE combined with lenvatinib and envafolimab was associated with encouraging antitumor activity and a relatively high conversion-to-resection rate, with an acceptable safety profile. However, the limited sample size and single-arm design preclude definitive causal conclusions, and gastrointestinal bleeding emerged as an important risk. These preliminary findings suggest the need for validation in larger, controlled trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.chictr.org.cn\/showproj.html?proj=222901<\/jats:ext-link>\n                      , identifier ChiCTR2400081945.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1802197","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T05:51:04Z","timestamp":1776837064000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["TACE plus lenvatinib and envafolimab for conversion therapy in unresectable HCC: a prospective pilot study"],"prefix":"10.3389","volume":"17","author":[{"given":"Yuhao","family":"Su","sequence":"first","affiliation":[{"name":"Liver Transplantation Center and HBP Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxin","family":"Liang","sequence":"additional","affiliation":[{"name":"Liver Transplantation Center and HBP Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deyuan","family":"Zhong","sequence":"additional","affiliation":[{"name":"Liver Transplantation Center and HBP Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yahui","family":"Chen","sequence":"additional","affiliation":[{"name":"Liver Transplantation Center and HBP Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Wang","sequence":"additional","affiliation":[{"name":"Liver Transplantation Center and HBP Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinyan","family":"Yang","sequence":"additional","affiliation":[{"name":"Liver Transplantation Center and HBP Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongtao","family":"Yan","sequence":"additional","affiliation":[{"name":"Liver Transplantation Center and HBP Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolun","family":"Huang","sequence":"additional","affiliation":[{"name":"Liver Transplantation Center and HBP Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J Hepatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3350\/cmh.2023.0125","article-title":"Recent advances in the management of hepatocellular carcinoma","volume":"30","author":"Sankar","year":"2024","journal-title":"Clin Mol Hepatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.jhep.2025.10.020","article-title":"BCLC strategy for prognosis prediction and treatment recommendations: The 2025 update","volume":"84","author":"Reig","year":"2025","journal-title":"J Hepatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.annonc.2025.02.006","article-title":"Hepatocellular carcinoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"36","author":"Vogel","year":"2025","journal-title":"Ann Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1186\/s12885-024-12772-y","article-title":"Systemic conversion therapies for initially unresectable hepatocellular carcinoma: a systematic review and meta-analysis","volume":"24","author":"Xu","year":"2024","journal-title":"BMC Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.5582\/bst.2024.01394","article-title":"Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition)","volume":"18","author":"Tang","year":"2025","journal-title":"Biosci Trends"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.01.039","article-title":"Breakthroughs in hepatocellular carcinoma therapies","volume":"21","author":"Singal","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.772195","article-title":"Downstaging conversion therapy in patients with initially unresectable advanced hepatocellular carcinoma: An overview","volume":"11","author":"Sun","year":"2021","journal-title":"Front Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000000466","article-title":"AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"5430","DOI":"10.3390\/cancers13215430","article-title":"Locoregional therapies for hepatocellular carcinoma with portal vein tumor thrombosis","volume":"13","author":"Zane","year":"2021","journal-title":"Cancers Bsl"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.17226\/1626","article-title":"EASL clinical practice guidelines on the management of hepatocellular carcinoma","volume":"82","year":"2025","journal-title":"J Hepatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1159\/000546138","article-title":"Current perspectives on perioperative combination therapy for hepatocellular carcinoma","volume":"14","author":"Nishio","year":"2025","journal-title":"Liver Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1330","article-title":"Angiogenesis enhanced by treatment damage to hepatocellular carcinoma through the release of GDF15","volume":"7","author":"Dong","year":"2018","journal-title":"Cancer Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-318934","article-title":"Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial","volume":"69","author":"Kudo","year":"2020","journal-title":"Gut"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.01.012","article-title":"Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial","volume":"64","author":"Lencioni","year":"2016","journal-title":"J Hepatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(21)00110-2","article-title":"Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial","volume":"6","author":"Vogel","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-021-10184-9","article-title":"Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study","volume":"15","author":"Fu","year":"2021","journal-title":"Hepatol Int"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.09.051","article-title":"Targeted and immune-based therapies for hepatocellular carcinoma","volume":"156","author":"Greten","year":"2019","journal-title":"Gastroenterology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.10.029","article-title":"Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma","volume":"66","author":"Duffy","year":"2017","journal-title":"J Hepatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.816198","article-title":"Efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: A prospective, multi-center, real-world study","volume":"12","author":"You","year":"2022","journal-title":"Front Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2021.101851","article-title":"Effect of camrelizumab plus transarterial chemoembolization on massive hepatocellular carcinoma","volume":"46","author":"Zhang","year":"2022","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-023-09754-2","article-title":"Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study","volume":"33","author":"Jin","year":"2023","journal-title":"Eur Radiol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1057560","article-title":"Transarterial chemoembolization plus apatinib with or without camrelizumab for unresected hepatocellular carcinoma: A two-center propensity score matching study","volume":"12","author":"Zhu","year":"2022","journal-title":"Front Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2147\/jhc.s428980","article-title":"Transarterial chemoembolization plus lenvatinib and PD-1 inhibitors for hepatocellular carcinoma with main trunk portal vein tumor thrombus: A multicenter retrospective study","volume":"10","author":"Li","year":"2023","journal-title":"J Hepatocel Carcinoma"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.783480","article-title":"The efficacy of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: A multicenter retrospective study","volume":"11","author":"Cao","year":"2021","journal-title":"Front Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00262-024-03857-5","article-title":"Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study","volume":"74","author":"Meng","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/js9.0000000000004131","article-title":"Efficacy and safety of TACE plus lenvatinib with PD-1 inhibitor for unresectable huge hepatocellular carcinoma: a multicenter retrospective cohort study","author":"Liang","year":"2025","journal-title":"Int J Surg"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01671-w","article-title":"Envafolimab: first approval","volume":"82","author":"Markham","year":"2022","journal-title":"Drugs"},{"key":"B32","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s00384-025-04806-z","article-title":"The efficacy and safety of suvemcitug, envafolimab, and FOLFIRI in microsatellite-stable or mismatch repair-proficient colorectal cancer: preliminary results of a phase 2 study","volume":"40","author":"Liu","year":"2025","journal-title":"Int J Colorectal Dis"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1097\/js9.0000000000001960","article-title":"Efficacy and safety of combining short-course neoadjuvant chemoradiotherapy with envafolimab in locally advanced rectal cancer patients with microsatellite stability: a phase II PRECAM experimental study","volume":"111","author":"Wang","year":"2025","journal-title":"Int J Surg"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-022-01287-7","article-title":"Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors","volume":"40","author":"Shimizu","year":"2022","journal-title":"Invest New Drugs"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.70101","article-title":"Safety and efficacy of the first subcutaneous ICI, envafolimab, in the treatment of advanced lung cancer patients: a real-world study","volume":"16","author":"Dou","year":"2025","journal-title":"Thorac Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.adengl.2019.05.021","article-title":"Using the common terminology criteria for adverse events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr Engl Ed"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.20623","article-title":"MIFlowCyt: the minimum information about a flow cytometry experiment","volume":"73","author":"Lee","year":"2008","journal-title":"Cytomet A"},{"key":"B38","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.06.014","article-title":"Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial","volume":"57","author":"Bruix","year":"2012","journal-title":"J Hepatol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1159\/000547725","article-title":"Conversion therapy based on TACE\/HAIC-based treatment to improve the therapeutic effect of initially unresectable hepatocellular carcinoma","author":"Lin","year":"2025","journal-title":"Liver Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1046584","article-title":"Lenvatinib plus anti-PD-1 therapy represents a feasible conversion resection strategy for patients with initially unresectable hepatocellular carcinoma: A retrospective study","volume":"12","author":"Yi","year":"2022","journal-title":"Front Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1097\/as9.0000000000000057","article-title":"Conversion to resectability using transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for initially unresectable hepatocellular carcinoma","volume":"2","author":"Li","year":"2021","journal-title":"Ann Surg Open"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102367","article-title":"Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study","volume":"67","author":"Wu","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B44","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41392-024-01991-1","article-title":"Envafolimab plus lenvatinib and transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a prospective, single-arm, phase II study","volume":"9","author":"Chen","year":"2024","journal-title":"Signal Transduc Tgt Ther"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007366","article-title":"Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial","volume":"11","author":"Zhang","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1115109","article-title":"Sintilimab plus lenvatinib conversion therapy for intermediate\/locally advanced hepatocellular carcinoma: A phase 2 study","volume":"13","author":"Wang","year":"2023","journal-title":"Front Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.610636","article-title":"Narrow-margin hepatectomy resulted in higher recurrence and lower overall survival for R0 resection hepatocellular carcinoma","volume":"10","author":"Liu","year":"2020","journal-title":"Front Oncol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"4093","DOI":"10.3390\/cancers16234093","article-title":"Update on resection strategies for hepatocellular carcinoma: a narrative review","volume":"16","author":"Lee","year":"2024","journal-title":"Cancers Bsl"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2022.810479","article-title":"Prognostic impact of surgical margin in hepatectomy on patients with hepatocellular carcinoma: a meta-analysis of observational studies","volume":"9","author":"Lin","year":"2022","journal-title":"Front Surg"},{"key":"B50","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/s41392-025-02427-0","article-title":"Transarterial chemoembolization plus atezolizumab and bevacizumab in patients with intermediate hepatocellular carcinoma: a single-arm, phase 2 trial","volume":"10","author":"Wang","year":"2025","journal-title":"Signal Transduc Tgt Ther"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4090","article-title":"Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: results from the IMbrave150 trial","volume":"10","author":"Salem","year":"2021","journal-title":"Cancer Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2024.102390","article-title":"Predictive value of circulating immune cell changes in response to PD-1 blockade and TKI therapy in patients with hepatocellular carcinoma","volume":"48","author":"Wang","year":"2024","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.887186","article-title":"The dynamic role of NK cells in liver cancers: role in HCC and HBV associated HCC and its therapeutic implications","volume":"13","author":"Sajid","year":"2022","journal-title":"Front Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3390\/cells10061332","article-title":"Natural killer cells and T cells in hepatocellular carcinoma and viral hepatitis: current status and perspectives for future immunotherapeutic approaches","volume":"10","author":"Kalathil","year":"2021","journal-title":"Cells"},{"key":"B55","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/nejmoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N Engl J Med"},{"key":"B56","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1186\/s12935-021-02200-7","article-title":"Efficacy and safety of lenvatinib monotreatment and lenvatinib-based combination therapy for patients with unresectable hepatocellular carcinoma: a retrospective, real-world study in China","volume":"21","author":"Zhu","year":"2021","journal-title":"Cancer Cell Int"},{"key":"B57","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00253-007-1142-2","article-title":"Properties, production, and applications of camelid single-domain antibody fragments","volume":"77","author":"Harmsen","year":"2007","journal-title":"Appl Microbiol Biotechnol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1802197\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T05:51:05Z","timestamp":1776837065000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1802197\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":57,"alternative-id":["10.3389\/fimmu.2026.1802197"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1802197","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"article-number":"1802197"}}